Skip to main content
Premium Trial:

Request an Annual Quote

Pressure Biosciences' Q3 Revenues Climb 19 Percent

NEW YORK (GenomeWeb News) – Pressure Biosciences today reported that its third-quarter 2009 revenues increased 19 percent on higher grant revenue and a growing number of installations of its Barocycler instruments.

The South Easton, Mass.-based firm brought in total revenues of $317,427 for the three-month period ended Sept. 30, compared to $265,662 for the third quarter of 2008. Revenues from its pressure cycling technology products and services were $204,584 versus $222,825 in the comparable quarter of 2008, while its grant revenue increased to $112,843 from $42,837.

Pressure Biosciences said that it installed 20 of its Barocycler instruments during the quarter, compared to seventeen in the third quarter of 2008.

Its net loss for the quarter declined to $775,449, or $.35 per share, from $1.1 million, or $.50 per share.

The firm cut its spending year over year, with R&D expenses down 27 percent at $273,286 versus $376,552 the year before. Its SG&A expenses fell around 16 percent to $724,228 from $866,263.

Pressure Biosciences finished the quarter with $1.4 million in cash and cash equivalents.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.